Comparison of different brands of IVIg in an in vitro model of immune neuropathy

Gang Zhang; Pablo H.H. Lopez; Kazim A. Sheikh

doi:10.1016/j.jneuroim.2005.12.001

Comparison of different brands of IVIg in an in vitro model of immune neuropathy

Gang Zhang, Pablo H.H. Lopez, Kazim A. Sheikh

School of Medicine

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Intravenous immunoglobulin (IVIg) is used for the treatment of a number of autoimmune neurological disorders. Whether different brands of IVIg or different lots of the same brand are comparably efficacious for the treatment of neurological disorders is not clear. To examine this issue we compared the efficacy of different brands and/or lots of IVIg in a cell culture model of immune neuropathy. We report that products examined were equally effective and there was no lot-to-lot variability in our experimental model. These findings support the notion that efficacy of different IVIg products is comparable in a standardized model.

Original language	English (US)
Pages (from-to)	200-203
Number of pages	4
Journal	Journal of Neuroimmunology
Volume	173
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2005.12.001
State	Published - Apr 2006

Keywords

CIDP
Guillain-Barré syndrome
IVIg
Immune neuropathies
Peripheral neuropathies

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2005.12.001

Cite this

@article{02721af4a5ff49b2bfd0de1adeb5a188,

title = "Comparison of different brands of IVIg in an in vitro model of immune neuropathy",

abstract = "Intravenous immunoglobulin (IVIg) is used for the treatment of a number of autoimmune neurological disorders. Whether different brands of IVIg or different lots of the same brand are comparably efficacious for the treatment of neurological disorders is not clear. To examine this issue we compared the efficacy of different brands and/or lots of IVIg in a cell culture model of immune neuropathy. We report that products examined were equally effective and there was no lot-to-lot variability in our experimental model. These findings support the notion that efficacy of different IVIg products is comparable in a standardized model.",

keywords = "CIDP, Guillain-Barr{\'e} syndrome, IVIg, Immune neuropathies, Peripheral neuropathies",

author = "Gang Zhang and Lopez, {Pablo H.H.} and Sheikh, {Kazim A.}",

note = "Funding Information: This work was supported by grants from the National Institute of Health (NS42888) and the GBS Foundation. We thank Dr. Pamela Talalay for editorial discussion.",

year = "2006",

month = apr,

doi = "10.1016/j.jneuroim.2005.12.001",

language = "English (US)",

volume = "173",

pages = "200--203",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Comparison of different brands of IVIg in an in vitro model of immune neuropathy

AU - Zhang, Gang

AU - Lopez, Pablo H.H.

AU - Sheikh, Kazim A.

N1 - Funding Information: This work was supported by grants from the National Institute of Health (NS42888) and the GBS Foundation. We thank Dr. Pamela Talalay for editorial discussion.

PY - 2006/4

Y1 - 2006/4

N2 - Intravenous immunoglobulin (IVIg) is used for the treatment of a number of autoimmune neurological disorders. Whether different brands of IVIg or different lots of the same brand are comparably efficacious for the treatment of neurological disorders is not clear. To examine this issue we compared the efficacy of different brands and/or lots of IVIg in a cell culture model of immune neuropathy. We report that products examined were equally effective and there was no lot-to-lot variability in our experimental model. These findings support the notion that efficacy of different IVIg products is comparable in a standardized model.

AB - Intravenous immunoglobulin (IVIg) is used for the treatment of a number of autoimmune neurological disorders. Whether different brands of IVIg or different lots of the same brand are comparably efficacious for the treatment of neurological disorders is not clear. To examine this issue we compared the efficacy of different brands and/or lots of IVIg in a cell culture model of immune neuropathy. We report that products examined were equally effective and there was no lot-to-lot variability in our experimental model. These findings support the notion that efficacy of different IVIg products is comparable in a standardized model.

KW - CIDP

KW - Guillain-Barré syndrome

KW - IVIg

KW - Immune neuropathies

KW - Peripheral neuropathies

UR - http://www.scopus.com/inward/record.url?scp=33644941236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644941236&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2005.12.001

DO - 10.1016/j.jneuroim.2005.12.001

M3 - Article

C2 - 16413615

AN - SCOPUS:33644941236

SN - 0165-5728

VL - 173

SP - 200

EP - 203

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Comparison of different brands of IVIg in an in vitro model of immune neuropathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this